24/05/2010

Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy


Skouby S.O. Al-Azzawi F. Barlow D. Calaf-Alsina J. Ertüngealp E. Gompel A. Graziottin A. Hudita D. Pines A. Rozenberg S. Samsioe G. Stevenson J.C.
Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy
Maturitas, 51, 1 (2005), 8-14

CONDIVIDI SU

The main indication for HRT use in postmenopausal women remains the relief of menopausal symptoms. Treatment for up to five years does not add significantly to lifetime risk of breast cancer, but significantly decreases bone loss and risk of osteoporotic fractures. Some women may be susceptible to early thrombotic risk, but when appropriate HRT is given after individual clinical evaluation, the benefits will far outweigh any potential risks and the treatment should be recommended. Future research is needed to identify new indications for HRT and to diminish or abolish its potential risks.

top


Available documents:
Full text of the article


By courtesy of Elsevier

FAIR USE: The content of this paper can be downloaded, printed and read for strictly personal and non-profit use. Any citation for didactic and/or scientific purpose must quote the title of the document, the name of the author(s), the data of the book or journal, and the URL of the site (www.alessandragraziottin.it).

WARNING: Every therapy must be discussed, tailored, prescribed and monitored by the M.D. personally consulted. Every information presented in this website can not surrogate the personal relationship with the caring physician nor be utilized without specific medical advice.